East Meets West: Harmony but Not Uniformity

Zhi-Hong Liu

DOI: https://doi.org/10.1159/000382139

2015-01-01

Kidney Diseases

Abstract:In April 1966, at the Bath Musical Festival in England, Yehudi Menuhin was appointed as a full-fledged artistic director of the festival, and he decided to mark the occasion by taking on new challenges. He took the plunge into the language of Indian music by performing a sitar-violin duet with Ravi Shankar. The collaboration seemed inevitable and was a resounding success. The album ‘West Meets East’ by Yehudi Menuhin and Ravi Shankar, recorded after their fantastic duet at the festival, won a Grammy Award. It is now a legend and emphasizes the pursuit of true understanding, particularly in this interdependent world today. In art and medicine alike, an enhanced mutual recognition of particularities from the different regions of the world is beneficial for all. Exchange of knowledge and shared experiences improve global understanding and foster progress. Kidney diseases are an important mortality cause worldwide, and the burden and challenge of kidney diseases in global public health are described thoroughly in the editorial of Dr. G. Remuzzi in this issue [1]. The best way to reduce these enormous burdens is to prevent kidney diseases in the first place, through earlier diagnosis and better care for people with kidney diseases. However, glaring gaps and inequities in the diagnosis and treatment of kidney diseases persist both within and between countries. Global efforts are taking place to shoulder the burden of kidney diseases. Kidney Disease: Improving Global Outcomes (KDIGO) is a global organization that aims to improve the care and outcomes of kidney disease patients worldwide by promoting the coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines through its international board. The guidelines on the definition, staging and management of kidney diseases have had a tremendous impact on the awareness of kidney diseases and on related research [2]. In addition, the International Society of Nephrology (ISN) commission on the 0 by 25 initiative for acute kidney injury was aimed at eliminating preventable deaths from acute kidney injury by 2025 by calling for global strategies that permit the timely diagnosis and treatment of potentially reversible acute kidney injury for patients; this initiative has a particular emphasis on people in lower- and middle-income countries [3]. To achieve these goals, it is important have a platform to identify the diversity of kidney diseases among different regions and to eliminate these disparities in development. Although the estimated prevalence of chronic kidney diseases in China is similar to that reported for developed countries, the etiology differs from that of Western countries. Data from the Chinese Renal Data System revealed that glomerular disease was the most common cause of end-stage renal disease (ESRD) [4], a finding that was different from that reported for developed countries, such as the USA [5] and UK [6], where the major cause of ESRD is diabetic nephropathy (DN). The KDIGO clinical practice guidelines for glomerulonephritis are based on evidence from 765 references, only 10 of which are from China [7]. We could not ignore this reality when implementing the KDIGO guidelines in China, and further relevant clinical trials are needed to close the gap. Treatment of IgA nephropathy (IgAN) remains a challenge. The efficacy and safety of mycophenolate mofetil (MMF) in IgAN have been observed in clinical trials from Europe, North America and Asia, but the results are inconsistent. A Belgian study assessed MMF at 2 g/day for 3 years versus placebo in patients with an average initial glomerular filtration rate (GFR) of 70 ml/1.73 m2 and proteinuria of 1.8 g/day. No difference in proteinuria reduction or preservation of GFR was observed [8]. Similarly, a North American study found no benefit over 24 months using a 1-year regimen of MMF 2 g/day versus placebo in patients with an initial GFR of 40 ml/1.73 m2 and proteinuria of 2.7 g/day [9]. By contrast, a Chinese study in patients with a mean initial GFR of 72 ml/ 1.73 m2 and a mean proteinuria of 1.8 g/day found a significant reduction in proteinuria at 18 months with MMF administered for 6 months over controls [10]. A 6-year follow-up of the same cohort demonstrated a kidney survival benefit [11]. Indeed, the different ethnicities may be a contributing factor to the differences in these studies, the design and execution of trials may be more germane for the heterogeneity of the results. Thus, the standardization of the methodology of a randomized control trial with a robust sample size and well-trained investigators will facilitate the conduct of high-quality clinical trials to obtain meaningful results. Enhancing kidney care is a critical task that requires efforts from both East and West. The journal Kidney Diseases was created to facilitate these efforts. The content of Kidney Diseases spans the areas of clinical and basic science relevant to kidney diseases. The journal covers all subjects of kidney diseases, including dialysis, transplantation and associated topics such as kidney-brain or kidney-heart interactions. The concept of the journal is to link Eastern and Western research and patient care on one platform to support communication and exchange of knowledge and opinion between the East and West. In this issue, IgAN, the most common glomerular disease worldwide, with a higher prevalence in Asia, and DN, the leading cause of ESRD in most Western countries, have been chosen as the main topics. International experts discuss the pathogenesis, treatment and research findings from the Western and Eastern points of view [12,13]. We heard from the duets that the prevalence of IgAN is higher in Asia than in Europe and North America. In Europe, IgAN affects men more frequently than women; this is not the case in China. Familial IgAN occurs more frequently in Europe than in Asia. Within Europe, the possible familial feature of IgAN is more evident in Southern than in Northern populations. O-glycosylation of IgA1 is a common finding in IgAN patients in the East and West. SNPs within the gene coding for the enzyme responsible for IgA1 O-glycosylation (C1GALT1) were reported in Chinese and European patients. Genetic variants in the HLA gene family were observed in populations from the East and West. Associations between IgAN and variants of the TAP1/PSMB and DEFA genes were observed in Asian but not in Western patients [14,15]. We also heard that the prevalence of DN is increasing in Asia and Western countries alike. The deletion (D) allele of the angiotensin-converting enzyme is associated with progression to ESRD in Asian patients with DN but not in Caucasians. Association between DN and polymorphism of the gene coding for acetyl coenzyme A carboxylase β has been reported in Asian and Western populations. Guidelines for DN treatment are evolving quickly both in Asia and Western countries based on the numerous clinical trials performed worldwide [16,17,18]. Such kind of dialogue between the East and West should define unresolved questions, encourage intense debate, and stimulate and prioritize future research in the field of kidney diseases. The editorial team therefore encourages scientific societies to affiliate with the journal and join its effort to improve interaction between nephrologists throughout the world and offer to their members a unique, global, and up-to-date source of information on kidney diseases. ‘Harmony but not uniformity’ are words of wisdom in a Chinese traditional philosophy created based on the theory of the origin of the universe, the universal biochemical theory and the humanistic value theory. This wisdom always supports a diversified existence and deems the integration and harmonious coexistence of different forms of existence as the development model of the universe. There is much ethnic, socioeconomic, environmental, health-care-resource and developmental heterogeneity between countries. These diversities have a major effect on the incidence, prevalence, and pattern of kidney diseases between the East and West. Unfortunately, despite the high prevalence and high mortality of kidney diseases, basic and clinical research on kidney diseases has lagged behind that of other medical fields. In particular, the number of randomized, controlled trials is lower than that in other medical subspecialties. There is a great need for additional research on kidney diseases. Undoubtedly, the concept of Kidney Diseases and the ad hoc team of international experts on its Editorial Board will establish a new unique landmark in research publications.